{"title":"抗磷脂综合征的病理生理学","authors":"P. R. Sada, H. Cohen, D. Isenberg","doi":"10.2174/1874303X01508010002","DOIUrl":null,"url":null,"abstract":"Advances in our knowledge of the pathogenic mechanisms of antiphospholipid syndrome have been achieved in the past few years. Apart from the well-known role of anti-β2-glycoprotein I antibodies, complement, endocrine and genetic factors and a variety of other molecules are now under investigation. These new approaches should lead to novel explanations and potential new treatment options.","PeriodicalId":38952,"journal":{"name":"Open Urology and Nephrology Journal","volume":"8 1","pages":"2-9"},"PeriodicalIF":0.0000,"publicationDate":"2015-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"The Pathophysiology of Antiphospholipid Syndrome\",\"authors\":\"P. R. Sada, H. Cohen, D. Isenberg\",\"doi\":\"10.2174/1874303X01508010002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Advances in our knowledge of the pathogenic mechanisms of antiphospholipid syndrome have been achieved in the past few years. Apart from the well-known role of anti-β2-glycoprotein I antibodies, complement, endocrine and genetic factors and a variety of other molecules are now under investigation. These new approaches should lead to novel explanations and potential new treatment options.\",\"PeriodicalId\":38952,\"journal\":{\"name\":\"Open Urology and Nephrology Journal\",\"volume\":\"8 1\",\"pages\":\"2-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Urology and Nephrology Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1874303X01508010002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Urology and Nephrology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874303X01508010002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Advances in our knowledge of the pathogenic mechanisms of antiphospholipid syndrome have been achieved in the past few years. Apart from the well-known role of anti-β2-glycoprotein I antibodies, complement, endocrine and genetic factors and a variety of other molecules are now under investigation. These new approaches should lead to novel explanations and potential new treatment options.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
